TRAVERE THERAPEUTICS INC (TVTX)
US89422G1076 - Common Stock
TVTX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. Both the profitability and financial health of TVTX have multiple concerns. TVTX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year TVTX has reported negative net income.
In the past year TVTX has reported a negative cash flow from operations.
In the past 5 years TVTX always reported negative net income.
In the past 5 years TVTX always reported negative operating cash flow.
1.2 Ratios
TVTX's Return On Assets of -69.68% is on the low side compared to the rest of the industry. TVTX is outperformed by 65.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.68% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-26.24%
ROA(5y)-26.16%
ROE(3y)-254.76%
ROE(5y)-182.13%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TVTX has a Gross Margin of 95.21%. This is amongst the best in the industry. TVTX outperforms 95.54% of its industry peers.
In the last couple of years the Gross Margin of TVTX has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for TVTX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.21% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.68%
GM growth 5Y-0.96%
2. Health
2.1 Basic Checks
TVTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
TVTX has more shares outstanding than it did 1 year ago.
TVTX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, TVTX has an improved debt to assets ratio.
2.2 Solvency
TVTX has an Altman-Z score of -3.36. This is a bad value and indicates that TVTX is not financially healthy and even has some risk of bankruptcy.
TVTX has a Altman-Z score (-3.36) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.36 |
ROIC/WACCN/A
WACC9.63%
2.3 Liquidity
A Current Ratio of 1.71 indicates that TVTX should not have too much problems paying its short term obligations.
TVTX has a Current ratio of 1.71. This is in the lower half of the industry: TVTX underperforms 79.50% of its industry peers.
TVTX has a Quick Ratio of 1.68. This is a normal value and indicates that TVTX is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.68, TVTX is not doing good in the industry: 79.32% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.71 | ||
| Quick Ratio | 1.68 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 4.35% over the past year.
TVTX shows a strong growth in Revenue. In the last year, the Revenue has grown by 30.37%.
Measured over the past years, TVTX shows a decrease in Revenue. The Revenue has been decreasing by -2.42% on average per year.
EPS 1Y (TTM)4.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.17%
Revenue 1Y (TTM)30.37%
Revenue growth 3Y-9.86%
Revenue growth 5Y-2.42%
Sales Q2Q%69.56%
3.2 Future
TVTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.41% yearly.
TVTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 25.46% yearly.
EPS Next Y16.93%
EPS Next 2Y31.52%
EPS Next 3Y30.23%
EPS Next 5Y16.41%
Revenue Next Year18.78%
Revenue Next 2Y37.56%
Revenue Next 3Y38.02%
Revenue Next 5Y25.46%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TVTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TVTX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
TVTX's earnings are expected to grow with 30.23% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.52%
EPS Next 3Y30.23%
5. Dividend
5.1 Amount
No dividends for TVTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TRAVERE THERAPEUTICS INC
NASDAQ:TVTX (11/22/2024, 8:10:05 PM)
After market: 18.25 0 (0%)18.25
-0.01 (-0.05%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.42B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.68% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.21% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.71 | ||
| Quick Ratio | 1.68 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)4.35%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y16.93%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)30.37%
Revenue growth 3Y-9.86%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y